search
close
Visitor Guide
| Test name | Pancreatic Cancer Options This test is available as an optional test for day checkups and overnight checkups.It is not performed as a stand-alone test. |
|---|---|
| Day of the week | Every Monday and Wednesday |
| Fee | 40,700 yen (tax included) |
| Points to note |
|
*The order of tests may change depending on the situation on the day.
In case of combined use with colonic optionwill start taking laxatives after MRCP and undergo a colonoscopy.
MRCP is a useful test for early detection of pancreatic cancer and is the core test of this option. By combining it with tumor marker testing, more accurate screening is possible.
MRCP is an abbreviation for Magnetic Resonance Cholangiopancreatography, and is a test method that uses an MRI device to non-invasively capture images of the pancreatic and bile ducts. By using a contrast agent, it is possible to observe in detail abnormalities such as strictures, dilation, and compression by tumors in the pancreatic and bile ducts.
This test involves taking an oral contrast agent (Bosdel) and then taking an MRI of the abdomen. This test does not involve radiation exposure and can be completed in a relatively short time.
Pancreatic cancer is considered one of the most difficult cancers to detect early, but MRCP increases the chances of detecting abnormalities in the pancreatic duct early. The presence of pancreatic cancer can cause changes in the pancreatic duct, such as narrowing, obstruction, or dilation, and these changes can be detected by MRCP.
The following tumor marker tests, when combined with MRCP imaging, are expected to improve the rate of early detection of pancreatic cancer. Each marker has its own characteristics, and combining multiple markers enables more accurate screening.
APOA2 protein is attracting attention as a useful biomarker for the early detection of pancreatic cancer. This test is performed at the same time as a regular blood draw, but because this test is outsourced, it takes about 5 to 7 days for the results to be available.
Since the blood concentration changes depending on the presence of pancreatic cancer, it is considered effective for screening for early-stage pancreatic cancer.
SPAN-1 is a tumor marker associated with pancreatic cancer. It is a carbohydrate antigen produced by pancreatic cancer cells, and its blood concentration increases in the presence of pancreatic cancer.
Combining this with other tumor markers improves diagnostic accuracy. This test is performed at the same time as regular blood sampling.
CA19-9 is the most widely used tumor marker for diagnosing pancreatic cancer, and its blood concentration is known to increase in the presence of pancreatic cancer.
However, since levels may rise even in benign diseases, a comprehensive judgment is made in conjunction with other test results. This is performed at the same time as regular blood sampling.
A gastroenterologist will evaluate the MRCP images and tumor marker results and make a judgment.
If any abnormal findings are found in the test results, we will refer you to a gastroenterologist if necessary.
